Advances in Antiplatelet Therapy: Agents in Clinical Development
Advances in Antiplatelet Therapy: Agents in Clinical Development
复制标题
DOI：
10.1016/j.amjcard.2008.11.023
复制
发表时间：
2009-02-02
影响因子：
2.8
通讯作者：
Jennings, Lisa K.
中科院分区：
文献类型：
--
作者：
Angiolillo, Dominick J.;Bhatt, Deepak L.;Jennings, Lisa K.
Antiplatelet agents are the cornerstone of treatment for patients with acute coronary syndromes and patients undergoing percutaneous coronary intervention. The current "gold standard" consists of a combination of aspirin and clopidogrel administered orally shortly before invasive procedures and then continued in the form of maintenance doses. Not all patients respond optimally to standard therapy. Resistance to the antiplatelet activity of both drugs when used either singly or in combination has been observed and may lead to treatment failure, including further atherothrombotic events. Potential limitations associated with the combined use of aspirin and clopidogrel have inspired clinical investigation into several promising new antiplatelet agents as potential additions or alternatives to standard therapy. The candidates include prasugrel, which has a mechanism similar to that of clopidogrel but with superior pharmacokinetics; ticagrelor, a nonthienopyridine that binds reversibly to the platelet P2Y(12) receptor; cangrelor, an intravenously administered analogue of ticagrelor; and various thrombin receptor antagonists. (C) 2009 Published by Elsevier Inc. (Am J Cardiol 2009;103[suppl]:40A-51A)
